Promising Developments and Strategic Partnerships Justify Buy Rating for Agenus
I'm PortAI, I can summarize articles.
Emily Bodnar, an analyst from H.C. Wainwright, has maintained a Buy rating on Agenus with a price target of $23.00. This rating is supported by promising developments in Agenus's clinical trials, particularly a Phase 1b trial showing significant survival benefits in cancer patients. Additionally, a strategic partnership with Zydus is expected to provide financial support for the Phase 3 BATTMAN trial. Recent compassionate use authorization in France further enhances the company's regulatory prospects, justifying the positive outlook.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments